Biogen Stock Declines 20.9% Year to Date: Time to Sell?

Zacks09-03

Biogen BIIB stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464938473?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","is_english":true,"pubTime":"2024-09-03 22:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2464938473","market":"us","top_or_hot":-1,"title":"Biogen Stock Declines 20.9% Year to Date: Time to Sell?","media":"Zacks","content":"<div>\n<p>Biogen BIIB stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-stock-declines-20-9-140600560.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Stock Declines 20.9% Year to Date: Time to Sell?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Stock Declines 20.9% Year to Date: Time to Sell?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-03 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biogen-stock-declines-20-9-140600560.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen BIIB stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-stock-declines-20-9-140600560.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PPD","symbol_name":"PPD, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/biogen-stock-declines-20-9-140600560.html","article_id":"2464938473","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464938473","pubTimestamp":1725372360,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Biogen BIIB stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.BIIB Stock Underperforms Industry, Sector & S&P 500. The company’s stock performance has been below most large drugmakers’ performance. Biogen's revenues declined 3.3% in the first six months of 2024. Sales of Biogen’s key multiple sclerosis  drugs like Tecfidera and Tysabri and spinal muscular atrophy  treatment, Spinraza are declining due to competitive pressure. Biogen has also regularly faced pipeline setbacks over the years, including the failure of its first Alzheimer’s drug, Aduhelm.However, with competition in the MS market intensifying, Biogen has successfully diversified its pipeline across neuroscience and adjacent therapeutic areas. Biogen has also strengthened its mid-to-late-stage pipeline with M&A deals, the most recent being HI-Bio. Some new drugs have the potential to drive Bi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PPD":"PPD, Inc.","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU0122379950.USD":"贝莱德世界健康科学A2","SAGE":"Sage Therapeutics","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","BK4561":"索罗斯持仓","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","CMS":"CMS能源","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4530":"医药外包概念","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BIIB":"渤健公司","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LLY":"礼来","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4139":"生物科技","LU0106831901.USD":"贝莱德世界金融基金A2","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV"},"translate_title":"Biogen股价今年迄今下跌20.9%：是时候卖出了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1,"PPD":1,"BIIB":1,"CMS":1,"LLY":0.7},"content_text":"Biogen BIIB stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.\nBIIB Stock Underperforms Industry, Sector & S&P 500\nImage Source: Zacks Investment Research\nThe company’s stock performance has been below most large drugmakers’ performance. Biogen's revenues declined 3.3% in the first six months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza are declining due to competitive pressure. Biogen has also regularly faced pipeline setbacks over the years, including the failure of its first Alzheimer’s drug, Aduhelm.\nHowever, with competition in the MS market intensifying, Biogen has successfully diversified its pipeline across neuroscience and adjacent therapeutic areas. Biogen has also strengthened its mid-to-late-stage pipeline with M&A deals, the most recent being HI-Bio. Some new drugs have the potential to drive Biogen’s long-term growth.  \nLet us discuss these factors in detail to understand how to play Biogen’s stock.\nKey Multiple Sclerosis Drugs and Spinraza Face Increased Competition\nSales of MS drugs and Spinraza are declining due to competitive pressure. Tecfidera revenues are declining as multiple generic versions have been launched in North America, Brazil and certain European countries. Regulatory applications seeking approval for a biosimilar referencing Tysabri have been approved in both the United States and Europe. A Tysabri biosimilar is now available in some European countries with additional launches in others and in the United States expected in 2024. Spinraza sales declined almost 2% in the first half of 2024 due to increased competitive pressure and a decrease in demand. Sales of MS drugs and Spinraza are not expected to show any significant improvement in the second half.\nBIIB’s New Drug Exceeds Expectations: Is it Enough?\nAmid declining demand for MS drugs and Spinraza, Biogen believes its new products, Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia and Zurzuvae for depression, have the potential to revive growth.\nBiogen and partner Eisai’s Leqembi/lecanemab gained full approval from the FDA for early Alzheimer’s disease in the United States and broad reimbursement from Centers for Medicare & Medicaid Services (CMS) in July 2023. Though the Leqembi launch was slow, sales have picked up in the first half of 2024 with the positive trend expected to continue in the second half.\nBiogen believes Leqembi has the potential to generate blockbuster sales as there remains a massive unmet need for Alzheimer's disease. Regulatory applications seeking approval of Leqembi are under review in Europe. Leqembi has been launched in China and Japan. A regulatory filing seeking approval for a maintenance intravenous dosing version of Leqembi is under review in the United States. At the same time, an application for the subcutaneous autoinjector is being filed on a rolling basis.\nBiogen and partner Sage Therapeutics’ SAGE Zurzuvae (zuranolone) was approved by the FDA to treat women with postpartum depression (PPD) in August 2023. The acquisition of Reata Pharmaceuticals in September 2023 added its newly approved rare disease drug, Skyclarys, for the treatment of Friedreich’s ataxia to Biogen’s portfolio. Skyclarys is seeing strong launch trends in the United States as well as the EU and is expected to be approved in 20 countries by the end of 2024 (approved in 12 countries outside the United States now). The Zurzuvae launch also exceeded the company’s internal expectations.\nHowever, the new drugs are not yet generating enough sales to make up for the declining revenues of MS drugs and Spinraza.\nBIIB’s Attractive Valuation & Rising Estimates\nBIIB’s stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company shares currently trade at 12.14 on a forward 12-month basis, lower than 20.68 for the industry. The stock is also trading below its 5-year mean of 13.56.\nBIIB Stock Valuation\nImage Source: Zacks Investment Research\nThe Zacks Consensus Estimate for earnings has risen from $15.62 to $16.08 per share for 2024, while for 2025, the number has declined from $17.37 to $17.26 per share over the past 30 days.\nBIIB’s Estimate Movement Mixed\nImage Source: Zacks Investment Research\nConclusion\nOther than competitive pressure on MS drugs and Spinraza, Biogen’s other troubles include the FDA approval of Eli Lilly’s LLY Alzheimer’s drug Kisunla (donanemab) in July 2024, which will pose significant competition to Leqembi. In July, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency gave a negative opinion regarding the marketing approval of Leqembi in the European Union.  While Eisai will request a re-examination of the opinion, this setback will delay approval in the EU. Biogen also expects costs to rise in the second half of the year.\nHowever, despite the expectation of higher operating costs in the second half, Biogen raised its operating income and earnings guidance for the year on the second-quarter conference call. The company also raised its top-line expectations for 2024. Its cost-saving initiatives under its “Fit for Growth” program and savings from the R&D portfolio prioritization efforts are pulling up profits.\nBiogen is definitely not the best large-cap drugmaker to have in one’s portfolio. However, consistently rising earnings estimates clearly highlight analysts’ optimistic outlook for further growth. The stock has also been consistently trading above its 50-day and 200-day moving averages since the end of July.\nBiogen’s reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested for now and not sell their shares immediately. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nThough there is still uncertainty about Biogen’s sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nSage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464938473"}